Document is current
Any future updates will be listed below
-
Authors
Wang, Na
Yu, Gefei
Wang, Zhen
Alnobani, Alla
Jeevaratnam, Suren
Zhang, Xue
McReynolds, Meghan
Chang, Yuzhou
Qi, Fangfang
Tauer, William
Rosenberg, Cassandra
Wren, Melissa
Ikezu, Tadafumi C.
Martens, Yuka A.
Wang, Minghui
Zhang, Bin
Carter, Gregory W.
Sasner, Michael
Holtzman, David M.
Peng, Junmin
Wu, Long-Jun
Kanekiyo, Takahisa
Liu, Chia-Chen
Bu, Guojun
-
Funding
Funding for this research was provided by:
NIH/NIA (U54AG054345)
NIH/NIA (1RF1AG055104)
NIH/NIA (U19AG069701)
- License Information
-
More Information
Article History
Received: 25 November 2025
Accepted: 16 March 2026
First Online: 24 March 2026
Declarations
:
: All animal procedures were approved by the Mayo Clinic Institutional Animal Care and Use Committee (IACUC) and followed NIH guidelines for the Care and Use of Laboratory Animals.
: All authors have approved the contents of this manuscript and provided consent for publication.
: G.B. consults for SciNeuro Pharmaceuticals. G.B. is a member of the advisory board of Neuron, an associate editor for Science Advances, and the editor-in-chief of Molecular Neurodegeneration. C.C.L. is an employee and Director at Simcere of America. D.M.H. is an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H is on the scientific advisory boards of C2N Diagnostics, Denali, Genentech, Cajal Therapeutics, Acta, and Switch and consults for Pfizer, Roche, and Annexon. D.M.H serves on the advisory board of Cell and Neuron and is on the editorial board of Annals of Neurology, Molecular Neurodegeneration, and Science Translational Medicine.
